Casefinding, Abstracting, and Data Quality for Gynecologic Cases
Overview
This domain covers the processes of identifying reportable gynecologic cancer cases, abstracting data accurately, and ensuring data quality. Key concepts: Casefinding methods include reviewing pathology reports, medical records, and disease indices. Reportable cases are defined by the cancer registry's standards (e.g., malignant neoplasms, in situ). Abstracting involves extracting data elements: patient demographics, tumor characteristics (site, histology, stage, grade), treatment, and outcomes. Data quality includes completeness, accuracy, and timeliness. Key data elements for gynecologic cancers: FIGO stage, tumor size, lymph node status, LVSI, biomarker status (e.g., HPV, p53, MSI), and treatment dates. Standard setters: Commission on Cancer (CoC), American College of Surgeons, state registries. Traps: misclassifying borderline ovarian tumors (not reportable), confusing primary site for overlapping tumors, and missing HPV status for cervical cancer.
Traps
Questions often test reportability rules. A common trap is whether borderline ovarian tumors are reportable (they are not, unless malignant). Another trap is the primary site for tumors involving multiple gynecologic organs (e.g., endometrial cancer extending to cervix is still endometrial primary). Also, be careful with histology codes: serous carcinoma vs. endometrioid. Data quality requires timely abstracting (within 6 months) and accuracy (e.g., correct stage).
Worked Example
A pathology report shows "borderline serous ovarian tumor." Is this reportable? No, borderline tumors are not reportable to cancer registries unless there is invasive malignancy. Rule of thumb: Report only malignant and in situ cases as defined by registry standards; borderline tumors are typically excluded.